Skip to main content
TipRanks
Go Ultimate75% OFF

Sutro Biopharma (S090) Stock Price & Analysis

1 Followers

S090 Stock Chart & Stats

€11.50€0.00(0.00%)
At close: 5:30 PM GMT+1
€20€25€30Apr 22May 11May 14Jul 20
Day’s Range
EUR 11.50 - EUR 11.50
52-Week Range
EUR 6.53 - EUR 36.00
Previous Close
EUR 11.50
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 134.69M
Enterprise Value
EUR 384.00M
Total Cash (Recent Filing)
EUR 142.18M
Total Debt (Recent Filing)
EUR 259.01M
Price to Earnings (P/E)
―
Beta
1.32
Next Earnings
Mar 29, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin

The approximately 97% TTM gross margin shows that Sutro’s underlying partnered and development-related economics can be attractive before operating expenses. If the company advances programs toward commercialization or expands collaboration activity, this margin profile could support meaningful operating leverage.

Advancing Clinical Pipeline

Rapidly moving multiple ADC programs into clinical testing strengthens the company’s development platform and creates several potential value drivers. A broader pipeline can improve the odds that clinical progress, partnering activity, or future approvals offset setbacks in individual programs.

Strategic Partner Execution

Astellas beginning patient dosing with another partnered ADC provides evidence that Sutro’s platform is being used beyond its wholly controlled pipeline. Continued partner execution can fund development, broaden validation of the technology, and create milestone or royalty opportunities over time.

Bears Say

Deteriorating Revenue Trend

The sharp TTM revenue decline indicates that collaboration and milestone-related revenue remains inconsistent rather than steadily compounding. Because Sutro depends largely on partner payments and development arrangements, weaker or delayed activity can prolong losses and make funding needs harder to plan.

Persistent Cash Burn

Operating and free cash outflows of roughly $129 million show that Sutro is consuming substantial cash to fund its operations and clinical pipeline. Persistent burn increases dependence on external capital, potentially limiting strategic flexibility and creating dilution or financing pressure.

Negative Stockholders’ Equity

Negative equity reflects the cumulative effect of losses and weakens the balance sheet’s financial flexibility even though headline debt is modest. This condition can make future capital raising more important and may constrain the company’s ability to absorb setbacks while funding clinical development.

Sutro Biopharma News

S090 FAQ

What was Sutro Biopharma’s price range in the past 12 months?
Sutro Biopharma lowest stock price was €6.53 and its highest was €36.00 in the past 12 months.
What is Sutro Biopharma’s market cap?
Sutro Biopharma’s market cap is €134.69M.
When is Sutro Biopharma’s upcoming earnings report date?
Sutro Biopharma’s next earnings report is estimated for Mar 29, 2027 (not yet confirmed), which is in 131 days.
How were Sutro Biopharma’s earnings last quarter?
Sutro Biopharma released its earnings results on Nov 12, 2026. The company reported -€1.724 earnings per share for the quarter, missing the consensus estimate of -€1.489 by -€0.235.
Is Sutro Biopharma overvalued?
According to Wall Street analysts Sutro Biopharma’s price is currently Undervalued.
Does Sutro Biopharma pay dividends?
Sutro Biopharma does not currently pay dividends.
What is Sutro Biopharma’s EPS estimate?
Sutro Biopharma’s EPS estimate is -1.32.
How many shares outstanding does Sutro Biopharma have?
Sutro Biopharma has 16,601,412 shares outstanding.
What happened to Sutro Biopharma’s price movement after its last earnings report?
Sutro Biopharma reported an EPS of -€1.724 in its last earnings report, missing expectations of -€1.489. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sutro Biopharma?
Hedge funds hold Sutro Biopharma shares: hedge funds decreased their holdings by 125.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology